Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: A cross-sectional study.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Nov 2019
Historique:
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 18 12 2019
Statut: ppublish

Résumé

Nonalcoholic fatty liver disease (NAFLD) is recognized as a hepatic manifestation of metabolic syndrome because of the association with visceral obesity. However, the association between NAFLD and subcutaneous fat accumulation remains unclear.The study population included 3197 participants in regular health checkups, who were both hepatitis B virus surface antigen and hepatitis C virus antibody-negative, and consumed <20 g of alcohol per day. They were divided according to 4 quantiles of subcutaneous fat area (SFA) and visceral fat area (VFA) on computed tomography. Fatty liver was diagnosed using ultrasonography (FL-US).The prevalence of FL-US increased across the SFA categories, even after adjusting for the VFA, in both men (P < .001) and women (P < .001). This significant association between FL-US and the SFA was already detected from the second SFA quantile. It is noteworthy that the mean body mass index (BMI) of the subjects in the second quantile was 23.7 kg/m in men and 22.6 kg/m in women. Independent positive associations were observed between alanine aminotransferase elevation, and both the SFA and VFA in men, while gamma glutamyl transpeptidase elevation was independently associated with the VFA, but not the SFA, in both men and women. Similarly, the components of metabolic syndrome were independently associated with the VFA, but were less strongly associated (or not associated at all) with the SFA.This cross-sectional study suggests that NAFLD is independently associated with both visceral and subcutaneous adiposity ab initio, which is a characteristic that distinguishes NAFLD from other components of metabolic syndrome.

Identifiants

pubmed: 31725632
doi: 10.1097/MD.0000000000017879
pii: 00005792-201911150-00034
pmc: PMC6867727
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e17879

Références

Diabetes Care. 2009 Jun;32(6):1068-75
pubmed: 19244087
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Nat Commun. 2013;4:1528
pubmed: 23443556
J Gastroenterol. 2006 May;41(5):462-9
pubmed: 16799888
J Clin Invest. 2004 Jun;113(11):1582-8
pubmed: 15173884
J Atheroscler Thromb. 2011;18(3):177-81
pubmed: 21041983
Clin Gastroenterol Hepatol. 2016 Jan;14(1):132-8.e4
pubmed: 26226099
Diabetes. 2003 Jun;52(6):1364-70
pubmed: 12765945
Gastroenterology. 2016 Jan;150(1):79-81.e2
pubmed: 26376348
Nature. 2006 Dec 14;444(7121):881-7
pubmed: 17167477
Eur J Gastroenterol Hepatol. 2012 Jul;24(7):805-10
pubmed: 22546752
Arteriosclerosis. 1990 Jul-Aug;10(4):493-6
pubmed: 2196039
N Engl J Med. 2000 Apr 27;342(17):1266-71
pubmed: 10781624
J Gastroenterol. 2014 Oct;49(10):1406-13
pubmed: 24170184
Crit Rev Clin Lab Sci. 2001 Aug;38(4):263-355
pubmed: 11563810
Physiol Rev. 2013 Jan;93(1):359-404
pubmed: 23303913
J Atheroscler Thromb. 2018 Sep 1;25(9):846-984
pubmed: 30135334
Nihon Rinsho. 2009 Feb;67(2):297-300
pubmed: 19202902
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
Dis Markers. 2015;2015:818570
pubmed: 26543300
J Gastroenterol. 2015 Jan;50(1):95-108
pubmed: 24619537
Nutr J. 2016 Jan 06;15:2
pubmed: 26732788
Diabetologia. 2013 Jul;56(7):1638-48
pubmed: 23620060
J Clin Invest. 2005 May;115(5):1343-51
pubmed: 15864352
Metabolism. 2009 Aug;58(8):1200-7
pubmed: 19428036
Diabetes. 2007 Apr;56(4):1010-3
pubmed: 17287468

Auteurs

Takeshi Kure (T)

Department of Hepatology, Kagoshima Kouseiren Hospital, Yojirou, Kagoshima, Japan.
Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.
Department of Gastroenterology, National Hospital Organization Kagoshima Medical Center, Shiroyama-cho, Kagoshima, Japan.

Seiichi Mawatari (S)

Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Yasushi Imamura (Y)

Department of Hepatology, Kagoshima Kouseiren Hospital, Yojirou, Kagoshima, Japan.

Kohei Oda (K)

Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Kotaro Kumagai (K)

Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Yasunari Hiramine (Y)

Department of Hepatology, Kagoshima Kouseiren Hospital, Yojirou, Kagoshima, Japan.

Hironori Miyahara (H)

Medical Health Care Center, Kagoshima Kouseiren Hospital, Yojirou, Kagoshima, Japan.

Shuji Kanmura (S)

Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Akihiro Moriuchi (A)

Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.
Department of Gastroenterology, National Hospital Organization Kagoshima Medical Center, Shiroyama-cho, Kagoshima, Japan.

Hirofumi Uto (H)

Center for Digestive and Liver Diseases, Miyazaki Medical Center Hospital, Takamatsu-cho, Miyazaki, Japan.

Masahisa Horiuchi (M)

Department of Hygiene and Health Promotion Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Akio Ido (A)

Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH